The AIM-traded neuroscience imaging and biomarker analytics specialist said the update replaced its previous forecast of £7.5m, which would have represented a 15% uplift.
Chief executive Bram Goorden said the stronger performance had been driven by “a continued uplift in contract wins, contract extensions, and revenue diversification,” adding that it demonstrated “the fruits” of the strategy put in place in 2024.
At 0939 BST, shares in Ixico were up 15.69% at 9.4p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate